Log In
Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
Forgot your password?
Log In
Don't have an account? Sign Up Here
Join Us
Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
I agree to TheMaven's
Terms
and
Policy
Sign Up
Already have an account? Login here
JIM CRAMER
INVESTING
PERSONAL FINANCE
RETIREMENT
CRYPTO
MARKETS
HOW-TO
VIDEO
FINANCIAL ADVISOR CENTER
TECHNOLOGY
Search
Trade with Jim Cramer 14 Days Free
Join the Action Alerts PLUS Community today!
SUBSCRIBE NOW
LATEST NEWS
OPINION
Immunotherapy M&A In Focus as Celgene Buys Juno; Good, Bad of Activism--ICYMI
By Michael Brown
Jan 22, 2018 7:23 PM EST
PRESS RELEASES
Cellectis And Servier Execute The Amendment Confirming The Expansion Of Their Collaboration On UCART19 Products
By Business Wire
Mar 4, 2020 4:05 PM EST
PRESS RELEASES
Cellectis To Hold Fourth Quarter And Full Year 2019 Earnings Call On Thursday, March 5, 2020 At 7:30 AM EST
By Business Wire
Feb 25, 2020 4:30 PM EST
PRESS RELEASES
Cellectis And Servier Expand Collaboration On UCART19 Products
By Business Wire
Feb 18, 2020 4:30 PM EST
PRESS RELEASES
First Patient Dosed With Cellectis' New Allogeneic UCART123 Product Candidate For Relapsed/Refractory Acute Myeloid Leukemia
By Business Wire
Jan 15, 2020 4:30 PM EST
OPINION
Immunotherapy M&A In Focus as Celgene Buys Juno; Good, Bad of Activism--ICYMI
By Michael Brown
Jan 22, 2018 7:23 PM EST
STOCKS
Immunotherapy stocks power higher on Celgene-Juno deal
By Armie Margaret Lee
Jan 22, 2018 12:03 PM EST
HEALTH
Gene Editing Company Joins NASDAQ, Jumps Over 20% on First Day
By Melissa Angell
Jul 21, 2017 12:26 PM EDT
STOCKS
Tired of hearing about Blue Apron's fall? Check out the next wave of talked about IPOs
By Michael Brown
Jul 17, 2017 12:12 PM EDT
HEALTH
Move Over GMO's: IPO for Gene Editor Calyxt Launches Next Week
By Melissa Angell
Jul 10, 2017 5:09 PM EDT
STOCKS
Cellectis gains FDA nod to test new gene-edited cancer treatment
By Gregg Greenberg
Feb 7, 2017 12:27 PM EST
VIDEO
Cellectis Gets FDA Nod to Test New Gene-Edited Cancer Treatment
By Gregg Greenberg
Feb 7, 2017 12:14 PM EST
OPINION
13 companies to watch from MIT's smart 50 list, including 4 buys
By Robert Wasserman
Jul 21, 2016 7:48 AM EDT
MARKETS
Trade-Ideas: Cellectis (CLLS) Is Today's Weak On High Relative Volume Stock
By TheStreet Wire
Jul 8, 2016 10:33 AM EDT
VIDEO
CEOs Should Set Tone for Corporate Culture
By Rhonda Schaffler
Jun 16, 2016 11:19 AM EDT
OPINION
Managing corporate governance easier said than done
By Emily Stewart
Jun 6, 2016 5:11 PM EDT
STOCKS
Juno, Kite valuations at risk from simpler T-Cell cancer therapy
By Adam Feuerstein
Jan 26, 2016 11:15 AM EST
OPINION
Jim cramer's top takeaways: paychex and cellectis
By Scott Rutt
Dec 23, 2015 6:00 AM EST
JIM CRAMER
Jim Cramer's 'Mad Money' Recap: Welcome to Crazy Town
By Scott Rutt
Dec 22, 2015 8:09 PM EST
STOCKS
Juno, Kite, Novartis Yelp 'Oh Merde!' at Cellectis Off-the-Shelf CAR-T Data
By Adam Feuerstein
Nov 5, 2015 11:21 AM EST
INVESTING
Before the Move: Watch Cellectis Into UCART19 Data
By The Fly Staff
Nov 2, 2015 3:10 PM EST
INVESTING
Spark Therapeutics Trial Success Seen As Positive For Gene Therapy Sector
By The Fly Staff
Oct 5, 2015 10:53 AM EDT
INVESTING
Biotech Selloff Has No Effect on Cellectis Advances: CEO
By Gregg Greenberg
Aug 26, 2015 11:29 AM EDT
VIDEO
Biotech Selloff Does Not Dim Immunotherapy Advances Says Cellectis CEO
By Gregg Greenberg
Aug 26, 2015 11:05 AM EDT
OPINION
5 Stocks Ready for Breakouts
By Roberto Pedone
Aug 7, 2015 9:29 AM EDT
